Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.59 USD
Change Today +0.15 / 3.38%
Volume 20.0K
TTNP On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

400 Oyster Point Boulevard

Suite 505

South San Francisco, CA 94080

United States

Phone: 650-244-4990

Fax: 650-244-4956

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. The company’s product development programs utilize its proprietary long-term drug delivery platform, ProNeura, and focus primarily on treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Product Pipeline Probuphine The company is in the process of developing Probuphine for the maintenance treatment of opioid dependence. Upon subdermal insertion in a patient, Probuphine is designed to release medication continuously and maintain a stable, around the clock blood level of the drug buprenorphine, an approved agent for the treatment of opioid dependence. The company has licensed the rights to commercialize Probuphine in the U.S. and Canada to Braeburn Pharmaceuticals Sprl (Braeburn) and during 2014 the company has been supporting Braeburn and a team of experts to implement the program developed in cooperation with the FDA to address the items in the Complete Response letter issued in April 2013. This includes conducting a double blind, double dummy clinical study of a four implant dose of Probuphine in clinically stable patients who are receiving maintenance treatment with an approved sublingual formulation containing buprenorphine at a daily dose of 8mg or less. Intellectual Property In 2010, the United States Patent and Trademark Office issued a patent covering methods of using Probuphine for the treatment of opiate addiction. The company is the owner of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and ethylene-vinyl acetate, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent would expire in June 2024. Four U.S. continuation applications are pending which incorporate the use of buprenorphine with the continuous delivery technology. These patent applications include claims related to Probuphine for the potential treatment of opioid addiction and chronic pain. Related patents covering use of Probuphine with the continuous delivery technology for the treatment of opiate addiction have also issued in Australia, Canada, India, Japan, Mexico and New Zealand. Patents covering certain dopamine agonist implants have been issued or allowed in the United States, Europe, Japan, Australia, Canada, South Korea, Mexico, New Zealand, South Africa, and Hong Kong, while prosecution of the patent application continues in the United States, Israel, India, Japan, and China. The company holds a license from Sanofi-Aventis under certain issued U.S. patents and certain issued foreign patents relating to iloperidone and its methods of use in the treatment of psychiatric disorders, psychotic disorders and analgesia. The term of the U.S. patent that covers certain aspects of its iloperidone product expires in October 2016, excluding a six month extension possible if an approval of pediatric indication is obtained. History Titan Pharmaceuticals, Inc. was founded in 1992.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTNP:US $4.59 USD +0.15

TTNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $75.60 USD +1.54
Reckitt Benckiser Group PLC 6,309 GBp -37.00
View Industry Companies

Industry Analysis


Industry Average

Valuation TTNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.6x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TITAN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at